Company Dossier · Health Care
Regeneron Pharmaceuticals
- S&P 500
- Nasdaq-100
- Russell 1000
What Regeneron Pharmaceuticals is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $15.5 billion, up 9.3% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $3.76 billion, down 2.3% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $0.92 billion, up 3.4% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 31, 2025: $3.44 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (July 30, 2026): sentiment 0.60 on a −1 to +1 scale (mixed), confidence 0.80 of 1.Palanor Discourse
- Guidance in the last 90 days: 4 outlook figures raised, 0 lowered, 0 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 4, 2026): 2 risk factors added, 0 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $3.4 million on the open market.SEC Form 4
- 1,344 institutional managers reported a position at June 30, 2026 (−57 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 37 (67 a year earlier).U.S. Department of Labor (OFLC)
- Headlines in the last 30 days: 5, of which 0 read positive and 1 negative.Palanor headline tone
Company Posture
How Company Posture is measured →What Regeneron Pharmaceuticals is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Steady · Mixed
Expanding ↔ Retrenching
Steady
- Capital spending28th pct
- Debt raised—
- Buybacks vs capex39th pct
- Hiring filings96th pct
- Deals and private raises49th pct
- Patent publications39th pct
Confident ↔ Hedging
Mixed
- Call sentiment54th pct
- Call confidence59th pct
- Guidance changes97th pct
- Risk factors added27th pct
- Insider open-market trades44th pct
- + Guidance changes
- − Risk factors added
- + Call confidence
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver34th pct
- Stress filings48th pct
Credit
How these are built →Regeneron Pharmaceuticals's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.
Debt on the balance sheet
$2.7B
- Due within a year $0.7B
- Longer term $2.0B
- Default point $1.7B (short + ½ long)
Finance leases included · Jun 30, 2026 filing
Bonds priced, last 12 months
None
U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
In the news
Headlines that name Regeneron Pharmaceuticals, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NegativeRegeneron: The Easy Money Has Been Made (Rating Downgrade) (NASDAQ:REGN)
seekingalpha.com · via Marketaux · Oct 4, 2026
- NeutralVertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets
insidermonkey.com · via Marketaux · Oct 3, 2026
- NeutralRegeneron Pharmaceuticals (REGN) Reports Promising Ubamatamab Trial Results for Ovarian Cancer
gurufocus.com · via Marketaux · Oct 1, 2026
- NeutralRegeneron Pharmaceuticals (REGN) Reports Promising Phase 1/2 Trial Data Amid Stock Price Dip
gurufocus.com · via Marketaux · Oct 1, 2026
- NeutralRegeneron (REGN) Grants One-Time Performance Awards to CEO and CSO, Forms New Subsidiary
gurufocus.com · via Marketaux · Oct 1, 2026
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 21, 2026LobbyingLobbying report (REGENERON PHARMACEUTICALS, INC)third_quarter 2026 · $0.6 million
- Oct 20, 2026LobbyingLobbying report (BGR GOVERNMENT AFFAIRS)third_quarter 2026 · $0.1 million
- Oct 19, 2026LobbyingLobbying report (ARNOLD & PORTER KAYE SCHOLER LLP)third_quarter 2026 · $0.0 million
- Oct 16, 2026LobbyingLobbying report (CHECKMATE GOVERNMENT RELATIONS)third_quarter 2026 · $0.1 million
- Oct 15, 2026LobbyingLobbying report (THE WASHINGTON TAX & PUBLIC POLICY GROUP)third_quarter 2026 · $0.0 million
- Oct 13, 2026Patent
- Oct 13, 2026Patent
- Oct 13, 2026Patent
- Oct 13, 2026Patent
- Oct 6, 20268-KMaterial agreement signedItem 1.01
- Oct 6, 2026Patent
- Oct 6, 2026Trademark
- Oct 6, 2026Trademark
- Oct 6, 2026Trademark
- Oct 6, 2026Trademark
- Oct 6, 2026Trademark
- Sep 30, 20268-KDirector or officer changeItem 5.02
- Aug 3, 2026LobbyingLobbying report (CRANE STRATEGIES)second_quarter 2026 · $0.1 million
- Jul 21, 2026LobbyingLobbying report (REGENERON PHARMACEUTICALS, INC)second_quarter 2026 · $0.6 million
- Jul 20, 2026LobbyingLobbying report (ARNOLD & PORTER KAYE SCHOLER LLP)second_quarter 2026 · $0.1 million
- Jun 30, 2026Private creditLoans held by business development companies (Regeneron Pharmaceuticals, Inc.)$0.9 million at cost
- Jun 17, 20268-KShareholder vote resultsItem 5.07
- Feb 4, 202610-KAnnual report (10-K)2 risk factors added, 0 removed
- Jun 18, 20258-KShareholder vote resultsItem 5.07
- Feb 5, 202510-KAnnual report (10-K)0 risk factors added, 0 removed
- Feb 5, 202410-KAnnual report (10-K)1 risk factors added, 5 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Vertex Pharmaceuticals VRTX | $12.6B | $3.8B | Jun 30, 2026 |
| Biogen BIIB | $9.9B | $2.4B | Mar 31, 2026 |
| Gilead Sciences GILD | $30.5B | $12.9B | Jun 30, 2026 |
| Amgen AMGN | $38.1B | $10.2B | Jun 30, 2026 |
| Incyte INCY | $5.4B | — | Mar 31, 2026 |
| Neurocrine Biosciences NBIX | $3.4B | $0.6B | Jun 30, 2026 |
| United Therapeutics UTHR | $3.1B | $1.1B | Jun 30, 2026 |
| Exelixis EXEL | $2.4B | $1.2B | Jul 3, 2026 |